Search

Your search keyword '"Kneba, Michael"' showing total 1,047 results
Start Over Author "Kneba, Michael"
1,047 results on '"Kneba, Michael"'

201. Subclonal IKZF1 Deletions Indicate a Multiclonal Evolution In BCR-ABL1-Positive B-Cell Precursor ALL

Author

Boehm, Verena, primary, Lebenatus, Annett, additional, Bartels, Marius, additional, Nagel, Inga, additional, Trautmann, Heiko, additional, Gökbuget, Nicola, additional, Hoelzer, Dieter, additional, Pfeifer, Heike, additional, Siebert, Reiner, additional, Kneba, Michael, additional, Ottmann, Oliver, additional, and Brüggemann, Monika, additional

Published
2013
Full Text
View/download PDF

202. Allogeneic Stem Cell Transplantation with BEAM and Alemtuzumab Conditioning Immediately after Remission Induction Has Curative Potential in Advanced T-Cell Non-Hodgkin's Lymphoma

Author

Czajczynska, Anna, primary, Günther, Andreas, additional, Repp, Roland, additional, Humpe, Andreas, additional, Schub, Natalie, additional, Raff, Thorsten, additional, Nickelsen, Maike, additional, Schrauder, André, additional, Schrappe, Martin, additional, Kneba, Michael, additional, and Gramatzki, Martin, additional

Published
2013
Full Text
View/download PDF

203. Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group

Author

Fischer, Kirsten, Cramer, Paula, Busch, Raymonde, Boettcher, Sebastian, Bahlo, Jasmin, Schubert, Joeerg, Pflueger, Karl H., Schott, Silke, Goede, Valentin, Isfort, Susanne, von Tresckow, Julia, Fink, Anna-Maria, Buehler, Andreas, Winkler, Dirk, Kreuzer, Karl-Anton, Staib, Peter, Ritgen, Matthias, Kneba, Michael, Doehner, Hartmut, Eichhorst, Barbara F., Hallek, Michael, Stilgenbauer, Stephan, Wendtner, Clemens-Martin, Fischer, Kirsten, Cramer, Paula, Busch, Raymonde, Boettcher, Sebastian, Bahlo, Jasmin, Schubert, Joeerg, Pflueger, Karl H., Schott, Silke, Goede, Valentin, Isfort, Susanne, von Tresckow, Julia, Fink, Anna-Maria, Buehler, Andreas, Winkler, Dirk, Kreuzer, Karl-Anton, Staib, Peter, Ritgen, Matthias, Kneba, Michael, Doehner, Hartmut, Eichhorst, Barbara F., Hallek, Michael, Stilgenbauer, Stephan, and Wendtner, Clemens-Martin

Abstract

Purpose We investigated the safety and efficacy of bendamustine and rituximab (BR) in previously untreated patients with chronic lymphocytic leukemia (CLL). Patients and Methods In all, 117 patients, age 34 to 78 years, 46.2% of patients at Binet stage C, and 25.6% of patients age 70 years or older received BR chemoimmunotherapy for first-line treatment of CLL. Bendamustine was administered at a dose of 90 mg/m(2) on days 1 and 2 combined with 375 mg/m(2) rituximab on day 0 of the first course and 500 mg/m(2) on day 1 during subsequent courses for up to six courses. Results Overall response rate was 88.0% (95% CI, 80.7% to 100.0%) with a complete response rate of 23.1% and a partial response rate of 64.9%. Ninety percent of patients with del(11q), 94.7% with trisomy 12, 37.5% with del(17p), and 89.4% with unmutated IGHV status responded to treatment. After a median observation time of 27.0 months, median event-free survival was 33.9 months, and 90.5% of patients were alive. Grade 3 or 4 severe infections occurred in 7.7% of patients. Grade 3 or 4 adverse events for neutropenia, thrombocytopenia, and anemia were documented in 19.7%, 22.2%, and 19.7% of patients, respectively. Conclusion Chemoimmunotherapy with BR is effective and safe in patients with previously untreated CLL. J Clin Oncol 30:3209-3216. (C) 2012 by American Society of Clinical Oncology

Published
2012

204. Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Increases Overall Survival When Compared to 6 Courses of CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT in Mantle Cell Lymphoma: Final Analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net)

Author

Hermine, Olivier, Hoster, Eva, Walewski, Jan, Ribrag, Vincent, Brousse, Nicole, Thieblemont, Catherine, Bouabdallah, Reda, Dohner, Hartrnut, Feugier, Pierre, Forspointner, Roswitha, Haioun, Corinne, Kneba, Michael, Haenel, Mathias, Casasnovas, Olivier, Mertelsmann, Roland H., Hallek, Michael, Bosly, Andre, Nowacki, M., Klapper, Wolfram, Gisselbrecht, Christian, Coiffier, Bertrand, Unterhalt, Michael, Hiddemann, Wolfgang, Dreyling, Martin H., Hermine, Olivier, Hoster, Eva, Walewski, Jan, Ribrag, Vincent, Brousse, Nicole, Thieblemont, Catherine, Bouabdallah, Reda, Dohner, Hartrnut, Feugier, Pierre, Forspointner, Roswitha, Haioun, Corinne, Kneba, Michael, Haenel, Mathias, Casasnovas, Olivier, Mertelsmann, Roland H., Hallek, Michael, Bosly, Andre, Nowacki, M., Klapper, Wolfram, Gisselbrecht, Christian, Coiffier, Bertrand, Unterhalt, Michael, Hiddemann, Wolfgang, and Dreyling, Martin H.

Published
2012

205. Extended Follow up of the CLL8 Protocol, a Randomized Phase-III Trial of the German CLL Study Group (GCLLSG) Comparing Fludarabine and Cyclophosphamide (FC) to FC Plus Rituximab (FCR) for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): Results On Survival, Progression-Free Survival, Delayed Neutropenias and Secondary Malignancies Confirm Superiority of the FCR Regimen

Author

Fischer, Kirsten, Bahlo, Jasmin, Fink, Anna-Maria, Busch, Raymonde, Boettcher, Sebastian, Mayer, Jiri, Dreger, Peter, Maurer, Christian, Engelke, Anja, Kneba, Michael, Doehner, Hartmut, Eichhorst, Barbara F., Wendtner, Clemens-Martin, Stilgenbauer, Stephan, Hallek, Michael, Fischer, Kirsten, Bahlo, Jasmin, Fink, Anna-Maria, Busch, Raymonde, Boettcher, Sebastian, Mayer, Jiri, Dreger, Peter, Maurer, Christian, Engelke, Anja, Kneba, Michael, Doehner, Hartmut, Eichhorst, Barbara F., Wendtner, Clemens-Martin, Stilgenbauer, Stephan, and Hallek, Michael

Published
2012

206. Gene Mutations and Treatment Outcome in Chronic Lymphocytic Leukemia: Results From the CLL8 Trial

Author

Stilgenbauer, Stephan, Busch, Raymonde, Schnaiter, Andrea, Paschka, Peter, Rossi, Marianna, Doehner, Konstanze, Zenz, Thorsten, Buehler, Andreas, Winkler, Dirk, Edelmann, Jennifer, Mertens, Daniel, Bullinger, Lars, Kless, Sabrina, Mack, Silja, Boettcher, Sebastian, Ritgen, Matthias, Kneba, Michael, Jaeger, Ulrich, Lichter, Peter, Patten, Nancy, Wenger, Michael K., Mendila, Myriam, Fingerle-Rowson, Gunter, Cazzola, Mario, Wendtner, Clemens, Fink, Anna Maria, Fischer, Kirsten, Hallek, Michael, Doehner, Hartmut, Stilgenbauer, Stephan, Busch, Raymonde, Schnaiter, Andrea, Paschka, Peter, Rossi, Marianna, Doehner, Konstanze, Zenz, Thorsten, Buehler, Andreas, Winkler, Dirk, Edelmann, Jennifer, Mertens, Daniel, Bullinger, Lars, Kless, Sabrina, Mack, Silja, Boettcher, Sebastian, Ritgen, Matthias, Kneba, Michael, Jaeger, Ulrich, Lichter, Peter, Patten, Nancy, Wenger, Michael K., Mendila, Myriam, Fingerle-Rowson, Gunter, Cazzola, Mario, Wendtner, Clemens, Fink, Anna Maria, Fischer, Kirsten, Hallek, Michael, and Doehner, Hartmut

Published
2012

207. Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group

Author

Fischer, Kirsten, Cramer, Paula, Busch, Raymonde, Stilgenbauer, Stephan, Bahlo, Jasmin, Schweighofer, Carmen D., Boettcher, Sebastian, Staib, Peter, Kiehl, Michael, Eckart, Michael J., Kranz, Gabriele, Goede, Valentin, Elter, Thomas, Buehler, Andreas, Winkler, Dirk, Kneba, Michael, Doehner, Hartmut, Eichhorst, Barbara F., Hallek, Michael, Wendtner, Clemens-Martin, Fischer, Kirsten, Cramer, Paula, Busch, Raymonde, Stilgenbauer, Stephan, Bahlo, Jasmin, Schweighofer, Carmen D., Boettcher, Sebastian, Staib, Peter, Kiehl, Michael, Eckart, Michael J., Kranz, Gabriele, Goede, Valentin, Elter, Thomas, Buehler, Andreas, Winkler, Dirk, Kneba, Michael, Doehner, Hartmut, Eichhorst, Barbara F., Hallek, Michael, and Wendtner, Clemens-Martin

Abstract

Purpose The objective of this trial was to evaluate safety and efficacy of bendamustine combined with rituximab (BR) in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL). Patients and Methods Seventy-eight patients, including 22 patients with fludarabine-refractory disease (28.2%) and 14 patients (17.9%) with deletion of 17p, received BR chemoimmunotherapy. Bendamustine was administered at a dose of 70 mg/m(2) on days 1 and 2 combined with rituximab 375 mg/m(2) on day 0 of the first course and 500 mg/m(2) on day 1 during subsequent courses for up to six courses. Results On the basis of intent-to-treat analysis, the overall response rate was 59.0% (95% CI, 47.3% to 70.0%). Complete response, partial response, and nodular partial response were achieved in 9.0%, 47.4%, and 2.6% of patients, respectively. Overall response rate was 45.5% in fludarabine-refractory patients and 60.5% in fludarabine-sensitive patients. Among genetic subgroups, 92.3% of patients with del(11q), 100% with trisomy 12, 7.1% with del(17p), and 58.7% with unmutated IGHV status responded to treatment. After a median follow-up time of 24 months, the median event-free survival was 14.7 months. Severe infections occurred in 12.8% of patients. Grade 3 or 4 neutropenia, thrombocytopenia, and anemia were documented in 23.1%, 28.2%, and 16.6% of patients, respectively. Conclusion Chemoimmunotherapy with BR is effective and safe in patients with relapsed CLL and has notable activity in fludarabine-refractory disease. Major but tolerable toxicities were myelosuppression and infections. These promising results encouraged us to initiate a further phase II trial evaluating the BR regimen in patients with previously untreated CLL.

Published
2011

208. Prediction of Poor Outcome in CLL Patients Treated with FCR (Fludarabine, Cyclophosphamide, Rituximab) in the CLL8 Trial of the German CLL Study Group (GCLLSG)

Author

Fink, Anna, Busch, Raymonde, Pflug, Natali, Boettcher, Sebastian, Winkler, Dirk, Buehler, Andreas, Ritgen, Matthias, Fischer, Kirsten, Eichhorst, Barbara, Wendtner, Clemens-Martin, Mendila, Myriam, Wenger, Michael K., Doehner, Hartmut, Kneba, Michael, Stilgenbauer, Stephan, Hallek, Michael, Fink, Anna, Busch, Raymonde, Pflug, Natali, Boettcher, Sebastian, Winkler, Dirk, Buehler, Andreas, Ritgen, Matthias, Fischer, Kirsten, Eichhorst, Barbara, Wendtner, Clemens-Martin, Mendila, Myriam, Wenger, Michael K., Doehner, Hartmut, Kneba, Michael, Stilgenbauer, Stephan, and Hallek, Michael

Published
2011

209. Minimal Residual Disease (MRD) Re-Growth Kinetics Are An Independent Predictor for Progression Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) and Are Related to Biologically Defined CLL-Subgroups-Results From the CLL8 Trial of the German CLL Study Group (GCLLSG)

Author

Boeitcher, Sebastian, Ritgen, Matthias, Fischer, Kirsten, Stilgenbauer, Stephan, Busch, Raymonde, Fingerle-Rowson, Gunter R., Fink, Anna-Maria, Buehler, Andreas, Winkler, Dirk, Wenger, Michael K., Mendila, Myriam, Wendtner, Clemens, Eichhorst, Barbara, Doehner, Hartmut, Hallek, Michael, Kneba, Michael, Boeitcher, Sebastian, Ritgen, Matthias, Fischer, Kirsten, Stilgenbauer, Stephan, Busch, Raymonde, Fingerle-Rowson, Gunter R., Fink, Anna-Maria, Buehler, Andreas, Winkler, Dirk, Wenger, Michael K., Mendila, Myriam, Wendtner, Clemens, Eichhorst, Barbara, Doehner, Hartmut, Hallek, Michael, and Kneba, Michael

Published
2011

210. Second-Line Therapies After Treatment with Fludarabine, Cyclophosphamide, and Rituximab (FCR) or Fludarabine and Cyclophosphamid Alone (FC) for Chronic Lymphocytic Leukemia (CLL) within the CLL8-Protocol of the German CLL Study Group (GCLLSG)

Author

Cramer, Paula, Fink, Anna-Maria, Busch, Raymonde, Eichhorst, Barbara, Wendtner, Clemens-Martin, Pflug, Natali, Schubert, Friederike, Doehner, Hartmut, Rieger, Michael, Kneba, Michael, Mayer, Jiri, Hallek, Michael, Fischer, Kirsten, Cramer, Paula, Fink, Anna-Maria, Busch, Raymonde, Eichhorst, Barbara, Wendtner, Clemens-Martin, Pflug, Natali, Schubert, Friederike, Doehner, Hartmut, Rieger, Michael, Kneba, Michael, Mayer, Jiri, Hallek, Michael, and Fischer, Kirsten

Published
2011

211. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial

Author

Dreger, Peter, Doehner, Hartmut, Ritgen, Matthias, Boettcher, Sebastian, Busch, Raymonde, Dietrich, Sascha, Bunjes, Donald, Cohen, Sandra, Schubert, Joerg, Hegenbart, Ute, Beelen, Dietrich, Zeis, Matthias, Stadler, Michael, Hasenkamp, Justin, Uharek, Lutz, Scheid, Christof, Humpe, Andreas, Zenz, Thorsten, Winkler, Dirk, Hallek, Michael, Kneba, Michael, Schmitz, Norbert, Stilgenbauer, Stephan, Dreger, Peter, Doehner, Hartmut, Ritgen, Matthias, Boettcher, Sebastian, Busch, Raymonde, Dietrich, Sascha, Bunjes, Donald, Cohen, Sandra, Schubert, Joerg, Hegenbart, Ute, Beelen, Dietrich, Zeis, Matthias, Stadler, Michael, Hasenkamp, Justin, Uharek, Lutz, Scheid, Christof, Humpe, Andreas, Zenz, Thorsten, Winkler, Dirk, Hallek, Michael, Kneba, Michael, Schmitz, Norbert, and Stilgenbauer, Stephan

Abstract

The purpose of this prospective multicenter phase 2 trial was to investigate the long-term outcome of reduced-intensity conditioning allogeneic stem cell transplantation (alloSCT) in patients with poor-risk chronic lymphocytic leukemia. Conditioning was fludarabine/cyclophosphamide-based. Longitudinal quantitative monitoring of minimal residual disease (MRD) was performed centrally by MRD-flow or real-time quantitative polymerase chain reaction. One hundred eligible patients were enrolled, and 90 patients proceeded to alloSCT. With a median follow-up of 46 months (7-102 months), 4-year nonrelapse mortality, event-free survival (EFS) and overall survival (OS) were 23%, 42%, and 65%, respectively. Of 52 patients with MRD monitoring available, 27 (52%) were alive and MRD negative at 12 months after transplant. Four-year EFS of this subset was 89% with all event-free patients except for 2 being MRD negative at the most recent assessment. EFS was similar for all genetic subsets, including 17p deletion (17p-). In multivariate analyses, uncontrolled disease at alloSCT and in vivo T-cell depletion with alemtuzumab, but not 17p-, previous purine analogue refractoriness, or donor source (human leukocyte antigen-identical siblings or unrelated donors) had an adverse impact on EFS and OS. In conclusion, alloSCT for poor-risk chronic lymphocytic leukemia can result in long-term MRD-negative survival in up to one-half of the patients independent of the underlying genomic risk profile. This trial is registered at http://clinicaltrials.gov as NCT00281983. (Blood. 2010;116(14):2438-2447)

Published
2010

212. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study

Author

Pott, Christiane, Hoster, Eva, Delfau-Larue, Marie-Helene, Beldjord, Kheira, Böttcher, Sebastian, Asnafi, Vahid, Plonquet, Anne, Siebert, Reiner, Callet-Bauchu, Evelyne, Andersen, Niels, van Dongen, Jacques J M, Klapper, Wolfram, Berger, Françoise, Ribrag, Vincent, van Hoof, Achiel L, Trneny, Marek, Walewski, Jan, Dreger, Peter, Unterhalt, Michael, Hiddemann, Wolfgang, Kneba, Michael, Kluin-Nelemans, Hanneke C, Hermine, Olivier, Macintyre, Elizabeth, Dreyling, Martin, Pott, Christiane, Hoster, Eva, Delfau-Larue, Marie-Helene, Beldjord, Kheira, Böttcher, Sebastian, Asnafi, Vahid, Plonquet, Anne, Siebert, Reiner, Callet-Bauchu, Evelyne, Andersen, Niels, van Dongen, Jacques J M, Klapper, Wolfram, Berger, Françoise, Ribrag, Vincent, van Hoof, Achiel L, Trneny, Marek, Walewski, Jan, Dreger, Peter, Unterhalt, Michael, Hiddemann, Wolfgang, Kneba, Michael, Kluin-Nelemans, Hanneke C, Hermine, Olivier, Macintyre, Elizabeth, and Dreyling, Martin

Abstract

The prognostic impact of minimal residual disease (MRD) was analyzed in 259 patients with mantle cell lymphoma (MCL) treated within 2 randomized trials of the European MCL Network (MCL Younger and MCL Elderly trial). After rituximab-based induction treatment, 106 of 190 evaluable patients (56%) achieved a molecular remission (MR) based on blood and/or bone marrow (BM) analysis. MR resulted in a significantly improved response duration (RD; 87% vs 61% patients in remission at 2 years, P = .004) and emerged to be an independent prognostic factor for RD (hazard ratio = 0.4, 95% confidence interval, 0.1-0.9, P = .028). MR was highly predictive for prolonged RD independent of clinical response (complete response [CR], complete response unconfirmed [CRu], partial response [PR]; RD at 2 years: 94% in BM MRD-negative CR/CRu and 100% in BM MRD-negative PR, compared with 71% in BM MRD-positive CR/CRu and 51% in BM MRD-positive PR, P = .002). Sustained MR during the postinduction period was predictive for outcome in MCL Younger after autologous stem cell transplantation (ASCT; RD at 2 years 100% vs 65%, P = .001) and during maintenance in MCL Elderly (RD at 2 years: 76% vs 36%, P = .015). ASCT increased the proportion of patients in MR from 55% before high-dose therapy to 72% thereafter. Sequential MRD monitoring is a powerful predictor for treatment outcome in MCL. These trials are registered at www.clinicaltrials.gov as #NCT00209222 and #NCT00209209.

Published
2010

213. Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group

Author

Cramer, Paula, primary, Fink, Anna-Maria, additional, Busch, Raymonde, additional, Eichhorst, Barbara, additional, Wendtner, Clemens-Martin, additional, Pflug, Natali, additional, Langerbeins, Petra, additional, Bahlo, Jasmin, additional, Goede, Valentin, additional, Schubert, Friederike, additional, Döhner, Hartmut, additional, Stilgenbauer, Stephan, additional, Dreger, Peter, additional, Kneba, Michael, additional, Böttcher, Sebastian, additional, Mayer, Jiri, additional, Hallek, Michael, additional, and Fischer, Kirsten, additional

Published
2013
Full Text
View/download PDF

214. Phase II, randomized, double-blind placebo-controlled trial of nimotuzumab plus gemcitabine compared with gemcitabine alone in patients (pts) with advanced pancreatic cancer (PC).

Author

Strumberg, Dirk, primary, Schultheis, Beate, additional, Ebert, Matthias Philip, additional, Kerkhoff, A., additional, Hofheinz, Ralf Dieter, additional, Behringer, Dirk M., additional, Schmidt, Wolfgang E., additional, Goker, Erdem, additional, De Dosso, Sara, additional, Kneba, Michael, additional, Yalcin, Suayib, additional, Overkamp, Friedrich, additional, Schlegel, Frank, additional, Dommach, M., additional, Rohrberg, Robert, additional, Steinmetz, Tilman, additional, Reuter, Dirk, additional, and Bach, Ferdinand, additional

Published
2013
Full Text
View/download PDF

216. ALK-positive primary cutaneous T-cell-lymphoma (CTCL) with unusual clinical presentation and aggressive course.

Author

Wehkamp, Ulrike, Oschlies, Ilske, Nagel, Inga, Brasch, Jochen, Kneba, Michael, Günther, Andreas, Klapper, Wolfram, and Weichenthal, Michael

Subjects
LYMPHOMAS, ELOCUTION, CELL transplantation, TRANSPLANTATION of organs, tissues, etc., STEM cell transplantation
Abstract

Anaplastic lymphoma kinase (ALK) expression is uncommon in primary cutaneous T-cell-lymphomas (CTCL). We report the case of a patient who was initially diagnosed with small plaque parapsoriasis, and eventually developed an unusual manifestation of CTCL 6 years later. The disease was characterized by aggressively ulcerating plaques and tumors of the entire skin. Histopathology revealed monoclonal proliferation of atypical T-lymphocytes and CD30-positive blasts with expression of ALK and identification of an ATIC-ALK fusion protein. Extensive staging confirmed the primary cutaneous origin of the lymphoma. After failure of several conventional treatments including polychemotherapy, the patient finally achieved remission after receiving brentuximab-vedotin, alemtuzumab and subsequent allogeneic stem cell transplantation. In the following, the patient developed inflammatory cutaneous lesions that pathologically showed no evidence for lymphoma relapse or classical cutaneous graft-versus-host disease. The patient responded to immunosuppression, but finally died from multi-organ failure due to sepsis 8months after stem cell transplantation. This is a rare instance of ALK positivity in a CTCL, most likely resembling CD30+ transformed mycosis fungoides, because it was not typical for cutaneous anaplastic large cell lymphoma (ALCL). In contrast to its role in systemic ALCL as favorable prognostic marker, ALK expression here was associated with an aggressive course. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

218. Absolute BCR-ABL Transcript Levels At 3 Months but Not At Diagnosis Predict Survival of Chronic Myeloid Leukemia (CML) Patients On Imatinib Therapy

Author

Hanfstein, Benjamin, primary, Shlyakhto, Valeria, additional, Lauseker, Michael, additional, Erben, Philipp, additional, Saussele, Susanne, additional, Fabarius, Alice, additional, Proetel, Ulrike, additional, Schnittger, Susanne, additional, Kolb, Hans-Jochem, additional, Krause, Stefan W., additional, Schubert, Joerg, additional, Einsele, Hermann, additional, Hänel, Mathias, additional, Dengler, Jolanta, additional, Falge, Christiane, additional, Kanz, Lothar, additional, Neubauer, Andreas, additional, Kneba, Michael, additional, Stegelmann, Frank, additional, Pfreundschuh, Michael, additional, Waller, Cornelius F., additional, Spiekermann, Karsten, additional, Baerlocher, Gabriela M., additional, Pfirrmann, Markus, additional, Hasford, Joerg, additional, Hofmann, Wolf-Karsten, additional, Hehlmann, Rüdiger, additional, Hochhaus, Andreas, additional, and Müller, Martin C., additional

Published
2012
Full Text
View/download PDF

219. Secondary Malignancies in CML Patients – Data From the German CML Study IV

Author

Miranda, Manuel Barreto, primary, Lauseker, Michael, additional, Proetel, Ulrike, additional, Schreiber, Annette, additional, Hanfstein, Benjamin, additional, Baerlocher, Gabriela M., additional, Heim, Dominik, additional, Ehninger, Gerhard, additional, Hossfeld, Dieter K., additional, Kolb, Hans-Jochem, additional, Krause, Stefan W., additional, Nerl, Christoph, additional, Einsele, Hermann, additional, Hänel, Mathias, additional, Dengler, Jolanta, additional, Falge, Christiane, additional, Kanz, Lothar, additional, Neubauer, Andreas, additional, Kneba, Michael, additional, Stegelmann, Frank, additional, Pfreundschuh, Michael, additional, Waller, Cornelius F., additional, Spiekermann, Karsten, additional, Hofmann, Wolf-Karsten, additional, Müller, Martin C., additional, Pfirrmann, Markus, additional, Hochhaus, Andreas, additional, Hasford, Joerg, additional, Hehlmann, Rüdiger, additional, and Saussele, Susanne, additional

Published
2012
Full Text
View/download PDF

220. The CD19 Antibody MOR208 Efficiently Triggers Natural Killer Cell-Mediated Cytotoxicity Against Acute Lymphoblastic Leukemia Cells From Pediatric and Adult Patients

Author

Kellner, Christian, primary, Zhukovsky, Eugene A, additional, Brüggemann, Monika, additional, Kneba, Michael, additional, Schrauder, André, additional, Schrappe, Martin, additional, Repp, Roland, additional, Humpe, Andreas, additional, Gramatzki, Martin, additional, and Peipp, Matthias, additional

Published
2012
Full Text
View/download PDF

221. SF3B1, NOTCH1 and TP53 Mutations Do Not Affect the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 6-Year Follow-up of the Gcllsg CLL3X Trial

Author

Dreger, Peter, primary, Schnaiter, Andrea, additional, Rossi, Marianna, additional, Paschka, Peter, additional, Bühler, Andreas, additional, Zenz, Thorsten, additional, Dietrich, Sascha, additional, Böttcher, Sebastian, additional, Bunjes, Donald, additional, Stadler, Michael, additional, Uharek, Lutz, additional, Scheid, Christof, additional, Hegenbart, Ute, additional, Hallek, Michael, additional, Kneba, Michael, additional, Schmitz, Norbert, additional, Döhner, Hartmut, additional, and Stilgenbauer, Stephan, additional

Published
2012
Full Text
View/download PDF

222. CLL Subsets with Distinct Stereotyped B Cell Receptors Have Distinct Epigenetic Make-up, Even Beyond IGHV Gene Mutational Status: DNA Methylation Profiling of IGHV-Unmutated CLL Stereotyped Subsets #6 and #8

Author

Papakonstantinou, Nikos, primary, Gutwein, Jana, additional, Ammerpohl, Ole, additional, Koravou, Eva, additional, Belessi, Chrysoula, additional, Siebert, Reiner, additional, Kneba, Michael, additional, Ritgen, Matthias, additional, Stamatopoulos, Kostas, additional, and Pott, Christiane, additional

Published
2012
Full Text
View/download PDF

223. Complete Molecular Remission (CMR 4.5) of CML Is Induced Faster by Dose – Optimized Imatinib and Predicts Better Survival - Results From the Randomized CML-Study IV

Author

Hehlmann, Rüdiger, primary, Lauseker, Michael, additional, Hanfstein, Benjamin, additional, Müller, Martin C., additional, Schreiber, Annette, additional, Proetel, Ulrike, additional, Pfirrmann, Markus, additional, Haferlach, Claudia, additional, Schnittger, Susanne, additional, Einsele, Hermann, additional, Dengler, Jolanta, additional, Falge, Christiane, additional, Kanz, Lothar, additional, Neubauer, Andreas, additional, Kneba, Michael, additional, Stegelmann, Frank, additional, Pfreundschuh, Michael, additional, Waller, Cornelius F., additional, Spiekermann, Karsten, additional, Baerlocher, Gabriela M., additional, Ehninger, Gerhard, additional, Heim, Dominik, additional, Heimpel, Hermann, additional, Nerl, Christoph, additional, Krause, Stefan W., additional, Hossfeld, Dieter K., additional, Kolb, Hans-Jochem, additional, Hochhaus, Andreas, additional, Hasford, Joerg, additional, and Saussele, Susanne, additional

Published
2012
Full Text
View/download PDF

224. Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Increases Overall Survival When Compared to 6 Courses of CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT in Mantle Cell Lymphoma: Final Analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net)

Author

Hermine, Olivier, primary, Hoster, Eva, additional, Walewski, Jan, additional, Ribrag, Vincent, additional, Brousse, Nicole, additional, Thieblemont, Catherine, additional, Bouabdallah, Reda, additional, Dohner, Hartmut, additional, Feugier, Pierre, additional, Forspointner, Roswitha, additional, Haioun, Corinne, additional, Kneba, Michael, additional, Hänel, Mathias, additional, Casasnovas, Olivier, additional, Mertelsmann, Roland H., additional, Hallek, Michael, additional, Bosly, Andre, additional, Nowacki, M, additional, Klapper, Wolfram, additional, Gisselbrecht, Christian, additional, Coiffier, Bertrand, additional, Unterhalt, Michael, additional, Hiddemann, Wolfgang, additional, and Dreyling, Martin H., additional

Published
2012
Full Text
View/download PDF

225. Gene Mutations and Treatment Outcome in Chronic Lymphocytic Leukemia: Results From the CLL8 Trial

Author

Stilgenbauer, Stephan, primary, Busch, Raymonde, additional, Schnaiter, Andrea, additional, Paschka, Peter, additional, Rossi, Marianna, additional, Döhner, Konstanze, additional, Zenz, Thorsten, additional, Bühler, Andreas, additional, Winkler, Dirk, additional, Edelmann, Jennifer, additional, Mertens, Daniel, additional, Bullinger, Lars, additional, Kless, Sabrina, additional, Mack, Silja, additional, Böttcher, Sebastian, additional, Ritgen, Matthias, additional, Kneba, Michael, additional, Jäger, Ulrich, additional, Lichter, Peter, additional, Patten, Nancy, additional, Wenger, Michael K., additional, Mendila, Myriam, additional, Fingerle-Rowson, Gunter, additional, Cazzola, Mario, additional, Wendtner, Clemens, additional, Fink, Anna Maria, additional, Fischer, Kirsten, additional, Hallek, Michael, additional, and Döhner, Hartmut, additional

Published
2012
Full Text
View/download PDF

226. Impact of Balanced or Unbalanced Karyotype At Diagnosis On Prognosis of CML: Long-Term Observation From 1346 Patients of the Randomized CML Study IV

Author

Fabarius, Alice, primary, Haferlach, Claudia, additional, Hochhaus, Andreas, additional, Müller, Martin C., additional, Hanfstein, Benjamin, additional, Göhring, Gudrun, additional, Schlegelberger, Brigitte, additional, Jotterrand, Martine, additional, Proetel, Ulrike, additional, Hofmann, Wolf-Karsten, additional, Krause, Stefan W., additional, Einsele, Hermann, additional, Dengler, Jolanta, additional, Falge, Christiane, additional, Kanz, Lothar, additional, Neubauer, Andreas, additional, Kneba, Michael, additional, Stegelmann, Frank, additional, Pfreundschuh, Michael, additional, Waller, Cornelius F., additional, Spiekermann, Karsten, additional, Lauseker, Michael, additional, Pfirrmann, Markus, additional, Hasford, Joerg, additional, Hehlmann, Rüdiger, additional, and Saussele, Susanne, additional

Published
2012
Full Text
View/download PDF

227. Substantially Improved Outcome of Adult Burkitt Non-Hodgkin Lymphoma and Leukemia Patients with Rituximab and a Short-Intensive Chemotherapy; Report of a Large Prospective Multicenter Trial

Author

Hoelzer, Dieter, primary, Walewski, Jan, additional, Döhner, Hartmut, additional, Schmid, Mathias, additional, Hiddemann, Wolfgang, additional, Baumann, Anja, additional, Serve, Hubert, additional, Dührsen, Ulrich, additional, Hüttmann, Andreas, additional, Thiel, Eckhard, additional, Dengler, Jolanta, additional, Kneba, Michael, additional, Schuler, Markus, additional, Schmidt-Wolf, Ingo, additional, Beck, Joachim, additional, Hertenstein, Bernd, additional, Reichle, Albrecht, additional, Domanska-Czyz, Katarzyna, additional, Fietkau, Rainer, additional, Horst, Heinz-August, additional, Rieder, Harald, additional, Schwartz, Stefan, additional, Burmeister, Thomas, additional, and Goekbuget, Nicola, additional

Published
2012
Full Text
View/download PDF

228. Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group

Author

Fischer, Kirsten, primary, Cramer, Paula, additional, Busch, Raymonde, additional, Böttcher, Sebastian, additional, Bahlo, Jasmin, additional, Schubert, Jöerg, additional, Pflüger, Karl H., additional, Schott, Silke, additional, Goede, Valentin, additional, Isfort, Susanne, additional, von Tresckow, Julia, additional, Fink, Anna-Maria, additional, Bühler, Andreas, additional, Winkler, Dirk, additional, Kreuzer, Karl-Anton, additional, Staib, Peter, additional, Ritgen, Matthias, additional, Kneba, Michael, additional, Döhner, Hartmut, additional, Eichhorst, Barbara F., additional, Hallek, Michael, additional, Stilgenbauer, Stephan, additional, and Wendtner, Clemens-Martin, additional

Published
2012
Full Text
View/download PDF

229. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies

Author

Gökbuget, Nicola, primary, Kneba, Michael, additional, Raff, Thorsten, additional, Trautmann, Heiko, additional, Bartram, Claus-Rainer, additional, Arnold, Renate, additional, Fietkau, Rainer, additional, Freund, Mathias, additional, Ganser, Arnold, additional, Ludwig, Wolf-Dieter, additional, Maschmeyer, Georg, additional, Rieder, Harald, additional, Schwartz, Stefan, additional, Serve, Hubert, additional, Thiel, Eckhard, additional, Brüggemann, Monika, additional, and Hoelzer, Dieter, additional

Published
2012
Full Text
View/download PDF

230. Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial

Author

Dreger, Peter, primary, Döhner, Hartmut, additional, McClanahan, Fabienne, additional, Busch, Raymonde, additional, Ritgen, Matthias, additional, Greinix, Hildegard, additional, Fink, Anna-Maria, additional, Knauf, Wolfgang, additional, Stadler, Michael, additional, Pfreundschuh, Michael, additional, Dührsen, Ulrich, additional, Brittinger, Günter, additional, Hensel, Manfred, additional, Schetelig, Johannes, additional, Winkler, Dirk, additional, Bühler, Andreas, additional, Kneba, Michael, additional, Schmitz, Norbert, additional, Hallek, Michael, additional, and Stilgenbauer, Stephan, additional

Published
2012
Full Text
View/download PDF

231. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial

Author

Engert, Andreas, primary, Haverkamp, Heinz, additional, Kobe, Carsten, additional, Markova, Jana, additional, Renner, Christoph, additional, Ho, Antony, additional, Zijlstra, Josée, additional, Král, Zdenek, additional, Fuchs, Michael, additional, Hallek, Michael, additional, Kanz, Lothar, additional, Döhner, Hartmut, additional, Dörken, Bernd, additional, Engel, Nicole, additional, Topp, Max, additional, Klutmann, Susanne, additional, Amthauer, Holger, additional, Bockisch, Andreas, additional, Kluge, Regine, additional, Kratochwil, Clemens, additional, Schober, Otmar, additional, Greil, Richard, additional, Andreesen, Reinhard, additional, Kneba, Michael, additional, Pfreundschuh, Michael, additional, Stein, Harald, additional, Eich, Hans Theodor, additional, Müller, Rolf-Peter, additional, Dietlein, Markus, additional, Borchmann, Peter, additional, and Diehl, Volker, additional

Published
2012
Full Text
View/download PDF

233. Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial

Author

Böttcher, Sebastian, primary, Ritgen, Matthias, additional, Fischer, Kirsten, additional, Stilgenbauer, Stephan, additional, Busch, Raymonde M., additional, Fingerle-Rowson, Günter, additional, Fink, Anna Maria, additional, Bühler, Andreas, additional, Zenz, Thorsten, additional, Wenger, Michael Karl, additional, Mendila, Myriam, additional, Wendtner, Clemens-Martin, additional, Eichhorst, Barbara F., additional, Döhner, Hartmut, additional, Hallek, Michael J., additional, and Kneba, Michael, additional

Published
2012
Full Text
View/download PDF

234. Plasmablastic Posttransplant Lymphoma

Author

Zimmermann, Heiner, primary, Oschlies, Ilske, additional, Fink, Susanne, additional, Pott, Christiane, additional, Neumayer, Hans H., additional, Lehmkuhl, Hans, additional, Hauser, Ingeborg A., additional, Dreyling, Martin, additional, Kneba, Michael, additional, Gärtner, Barbara, additional, Anagnostopoulos, Ioannis, additional, Riess, Hanno, additional, Klapper, Wolfram, additional, and Trappe, Ralf U., additional

Published
2012
Full Text
View/download PDF

236. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study

Author

Fink, Anna Maria, Bahlo, Jasmin, Robrecht, Sandra, Al-Sawaf, Othman, Aldaoud, Ali, Hebart, Holger, Jentsch-Ullrich, Kathleen, Dörfel, Steffen, Fischer, Kirsten, Wendtner, Clemens-Martin, Nösslinger, Thomas, Ghia, Paolo, Bosch, Francesc, Kater, Arnon P, Döhner, Hartmut, Kneba, Michael, Kreuzer, Karl-Anton, Tausch, Eugen, Stilgenbauer, Stephan, Ritgen, Matthias, Böttcher, Sebastian, Eichhorst, Barbara, and Hallek, Michael

Abstract

The combined use of genetic markers and detectable minimal residual disease identifies patients with chronic lymphocytic leukaemia with poor outcome after first-line chemoimmunotherapy. We aimed to assess lenalidomide maintenance therapy in these high-risk patients.

Published
2017
Full Text
View/download PDF

237. Prediction of Poor Outcome in CLL Patients Treated with FCR (Fludarabine, Cyclophosphamide, Rituximab) in the CLL8 Trial of the German CLL Study Group (GCLLSG)

Author

Fink, Anna, primary, Busch, Raymonde, additional, Pflug, Natali, additional, Boettcher, Sebastian, additional, Winkler, Dirk, additional, Buehler, Andreas, additional, Ritgen, Matthias, additional, Fischer, Kirsten, additional, Eichhorst, Barbara, additional, Wendtner, Clemens-Martin, additional, Mendila, Myriam, additional, Wenger, Michael K., additional, Doehner, Hartmut, additional, Kneba, Michael, additional, Stilgenbauer, Stephan, additional, and Hallek, Michael, additional

Published
2011
Full Text
View/download PDF

238. Second-Line Therapies After Treatment with Fludarabine, Cyclophosphamide, and Rituximab (FCR) or Fludarabine and Cyclophosphamid Alone (FC) for Chronic Lymphocytic Leukemia (CLL) within the CLL8-Protocol of the German CLL Study Group (GCLLSG)

Author

Cramer, Paula, primary, Fink, Anna-Maria, additional, Busch, Raymonde, additional, Eichhorst, Barbara, additional, Wendtner, Clemens-Martin, additional, Pflug, Natali, additional, Schubert, Friederike, additional, Döhner, Hartmut, additional, Rieger, Michael, additional, Kneba, Michael, additional, Mayer, Jiri, additional, Hallek, Michael, additional, and Fischer, Kirsten, additional

Published
2011
Full Text
View/download PDF

239. Minimal Residual Disease (MRD) Re-Growth Kinetics Are An Independent Predictor for Progression Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) and Are Related to Biologically Defined CLL-Subgroups– Results From the CLL8 Trial of the German CLL Study Group (GCLLSG)

Author

Boettcher, Sebastian, primary, Ritgen, Matthias, additional, Fischer, Kirsten, additional, Stilgenbauer, Stephan, additional, Busch, Raymonde, additional, Fingerle-Rowson, Gunter R., additional, Fink, Anna-Maria, additional, Buehler, Andreas, additional, Winkler, Dirk, additional, Wenger, Michael K., additional, Mendila, Myriam, additional, Wendtner, Clemens, additional, Eichhorst, Barbara, additional, Döhner, Hartmut, additional, Hallek, Michael, additional, and Kneba, Michael, additional

Published
2011
Full Text
View/download PDF

240. Overall Outcome of Relapsed Acute Lymphoblastic Leukemia Can Be Improved by Stem Cell Transplantation and Early Treatment in Stage of Molecular Relapse

Author

Goekbuget, Nicola, primary, Stanze, Daniel, additional, Arnold, Renate, additional, Brueggemann, Monika, additional, Fietkau, Rainer, additional, Freund, Mathias, additional, Ganser, Arnold, additional, Ludwig, Wolf-Dieter, additional, Maschmeyer, Georg, additional, Raff, Thorsten, additional, Rieder, Harald, additional, Thiel, Eckhard, additional, Serve, Hubert, additional, Kneba, Michael, additional, and Hoelzer, Dieter, additional

Published
2011
Full Text
View/download PDF

241. Impact of Additional Cytogenetic Alterations At Diagnosis on Prognosis of CML: Long-Term Observation From 1151 Patients of the Randomized CML Study IV

Author

Fabarius, Alice, primary, Leitner, Armin, additional, Hochhaus, Andreas, additional, Müller, Martin C, additional, Haferlach, Claudia, additional, Göhring, Gudrun, additional, Schlegelberger, Brigitte, additional, Jotterand, Martine, additional, Reiter, Andreas, additional, Jung-Munkwitz, Susanne, additional, Proetel, Ulrike, additional, Schwaab, Juliana, additional, Hofmann, Wolf-Karsten, additional, Schubert, Joerg E. A., additional, Einsele, Hermann, additional, Ho, Anthony D., additional, Falge, Christiane, additional, Kanz, Lothar, additional, Neubauer, Andreas, additional, Kneba, Michael, additional, Stegelmann, Frank, additional, Pfreundschuh, Michael, additional, Waller, Cornelius F., additional, Hiddemann, Wolfgang, additional, Baerlocher, Gabriela M., additional, Lauseker, Michael, additional, Pfirrmann, Markus, additional, Saussele, Susanne, additional, Hehlmann, Rüdiger, additional, and Hasford, Joerg, additional

Published
2011
Full Text
View/download PDF

242. 4.19 Prediction of Poor Outcome in Chronic Lymphocytic Leukemia Patients treated with FCR (Fludarabine, Cyclophosphamide, Rituximab) in the CLL8 Trial of the German CLL Study Group

Author

Fink, Anna, primary, Busch, Raymonde, additional, Pflug, Natali, additional, Boettcher, Sebastian, additional, Winkler, Dirk, additional, Buehler, Andreas, additional, Ritgen, Matthias, additional, Fischer, Kirsten, additional, Eichhorst, Barbara, additional, Wendtner, Clemens-Martin, additional, Mendila, Myriam, additional, Wenger, Michael K., additional, Doehner, Hartmut, additional, Kneba, Michael, additional, Stilgenbauer, Stephan, additional, and Hallek, Michael, additional

Published
2011
Full Text
View/download PDF

243. Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group

Author

Fischer, Kirsten, primary, Cramer, Paula, additional, Busch, Raymonde, additional, Stilgenbauer, Stephan, additional, Bahlo, Jasmin, additional, Schweighofer, Carmen D., additional, Böttcher, Sebastian, additional, Staib, Peter, additional, Kiehl, Michael, additional, Eckart, Michael J., additional, Kranz, Gabriele, additional, Goede, Valentin, additional, Elter, Thomas, additional, Bühler, Andreas, additional, Winkler, Dirk, additional, Kneba, Michael, additional, Döhner, Hartmut, additional, Eichhorst, Barbara F., additional, Hallek, Michael, additional, and Wendtner, Clemens-Martin, additional

Published
2011
Full Text
View/download PDF

244. Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

Author

Topp, Max S., primary, Kufer, Peter, additional, Gökbuget, Nicola, additional, Goebeler, Mariele, additional, Klinger, Matthias, additional, Neumann, Svenja, additional, Horst, Heinz-A., additional, Raff, Thorsten, additional, Viardot, Andreas, additional, Schmid, Mathias, additional, Stelljes, Matthias, additional, Schaich, Markus, additional, Degenhard, Evelyn, additional, Köhne-Volland, Rudolf, additional, Brüggemann, Monika, additional, Ottmann, Oliver, additional, Pfeifer, Heike, additional, Burmeister, Thomas, additional, Nagorsen, Dirk, additional, Schmidt, Margit, additional, Lutterbuese, Ralf, additional, Reinhardt, Carsten, additional, Baeuerle, Patrick A., additional, Kneba, Michael, additional, Einsele, Hermann, additional, Riethmüller, Gert, additional, Hoelzer, Dieter, additional, Zugmaier, Gerhard, additional, and Bargou, Ralf C., additional

Published
2011
Full Text
View/download PDF

246. R-CHOP/R-DHAP Compared to R-CHOP Induction Followed by High Dose Therapy with Autologous Stem Cell Transplantation Induces Higher Rates of Molecular Remission In MCL: Results of the MCL Younger Intergroup Trial of the European MCL Network

Author

Pott, Christiane, primary, Hoster, Eva, additional, Beldjord, Kheira, additional, Macintyre, Elizabeth A., additional, Böttcher, Sebastian, additional, Asnafi, Vahid, additional, Siebert, Reiner, additional, Plonquet, Anne, additional, Callet-Bauchut, Evelyne, additional, Ribrag, Vincent, additional, Klapper, Wolfram, additional, Berger, Francoise, additional, Unterhalt, Michael, additional, Kneba, Michael, additional, Hiddemann, Wolfgang, additional, Dreyling, Martin H., additional, Hermine, Olivier, additional, and Delfau, Marie-Helene, additional

Published
2010
Full Text
View/download PDF

247. Allogeneic Stem Cell Transplantation Can Overcome the Adverse Prognostic Impact of TP53 Mutation In Chronic Lymphocytic Leukemia (CLL): Results From the GCLLSG CLL3x Trial

Author

Zenz, Thorsten, primary, Dreger, Peter, additional, Dietrich, Sascha, additional, Böttcher, Sebastian, additional, Ritgen, Matthias, additional, Winkler, Dirk, additional, Bühler, Andreas, additional, Bunjes, Donald, additional, Beelen, Dietrich, additional, Cohen, Sandra, additional, Hegenbart, Ute, additional, Zeis, Matthias, additional, Hallek, Michael, additional, Kneba, Michael, additional, Schmitz, Norbert, additional, Döhner, Hartmut, additional, and Stilgenbauer, Stephan, additional

Published
2010
Full Text
View/download PDF

248. Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Is Superior to 6 Courses CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT In Mantle Cell Lymphoma: Results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net)

Author

Hermine, Olivier, primary, Hoster, Eva, additional, Walewski, Jan, additional, Ribrag, Vincent, additional, Brousse, Nicole, additional, Thieblemont, Catherine, additional, Bouabdallah, Reda, additional, Stilgenbauer, Stephan, additional, Feugier, Pierre, additional, Forstpointner, Roswitha, additional, Haioun, Corinne, additional, Kneba, Michael, additional, Hänel, Mathias, additional, Casasnovas, Rene-Olivier, additional, Finke, Jürgen, additional, Hallek, Michael, additional, Wandt, Hannes, additional, Bosly, Andre, additional, Klapper, Wolfram, additional, Gisselbrecht, Christian, additional, Coiffier, Bertrand, additional, Hiddemann, Wolfgang, additional, Unterhalt, Michael, additional, and Dreyling, Martin H., additional

Published
2010
Full Text
View/download PDF

249. Genetics of Patients with F-Refractory CLL or Early Relapse After FC or FCR: Results From the CLL8 Trial of the GCLLSG

Author

Zenz, Thorsten, primary, Busch, Raymonde, additional, Fink, Anna, additional, Winkler, Dirk, additional, Fischer, Kirsten, additional, Bühler, Andreas, additional, Hoth, Patrick, additional, Fingerle-Rowson, Gunter R., additional, Kneba, Michael, additional, Boettcher, Sebastian, additional, Jäger, Ulrich, additional, Mendila, Myriam, additional, Wenger, Michael, additional, Lichter, Peter, additional, Hallek, Michael, additional, Döhner, Hartmut, additional, and Stilgenbauer, Stephan, additional

Published
2010
Full Text
View/download PDF

250. CD19/CD3 Bispecific Antibody Blinatumomab (MT-103) Is Highly Effective In Treatment of Patients with Minimal Residual Disease From Chemotherapy-Resistant B-Precursor Acute Lymphoblastic Leukemia

Author

Topp, Max S, primary, Zugmaier, Gerhard, additional, Goekbuget, Nicola, additional, Neumann, Svenja, additional, Horst, Heinz-August, additional, Raff, Thorsten, additional, Brueggemann, Monika, additional, Kneba, Michael, additional, Viardot, Andreas, additional, Schmid, Mathias, additional, Schaich, Markus, additional, Stelljes, Matthias, additional, Goebeler, Mariele, additional, Pfeiffer, Heike, additional, Ottmann, Oliver, additional, Burmeister, Thomas, additional, Degenhard, Evelyn, additional, Schmidt, Margit, additional, Scheele, Jürgen, additional, Einsele, Hermann, additional, Kufer, Peter, additional, Klinger, Matthias, additional, Nagorsen, Dirk, additional, Hoelzer, Dieter, additional, and Bargou, Ralf, additional

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results